US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

NAMSW NewAmsterdam Pharma Company NV

9.02

-0.43 (-4.55%)

Última actualización: 14:16:06

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/13/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

03/28/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for NAP PoolCo B.V.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

NewAmsterdam Pharma Comp... (NASDAQ:NAMSW)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Haga Click aquí para más Gráficas NewAmsterdam Pharma Comp....

NewAmsterdam Pharma Comp... (NASDAQ:NAMSW)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024

Haga Click aquí para más Gráficas NewAmsterdam Pharma Comp....

Noticias sobre NewAmsterdam Pharma Company NV NAMSW

Form 8-K - Current report
Miércoles 20 de Noviembre 2024 (1 día hace) • Edgar (US Regulatory)

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
Miércoles 20 de Noviembre 2024 (1 día hace) • GlobeNewswire Inc.

Form 8-K - Current report
Lunes 18 de Noviembre 2024 (3 días hace) • Edgar (US Regulatory)

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
Lunes 18 de Noviembre 2024 (3 días hace) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Miércoles 13 de Noviembre 2024 (1 semana hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Miércoles 6 de Noviembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Miércoles 6 de Noviembre 2024 (2 semanas hace) • Edgar (US Regulatory)

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Miércoles 6 de Noviembre 2024 (2 semanas hace) • GlobeNewswire Inc.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viernes 1 de Noviembre 2024 (3 semanas hace) • GlobeNewswire Inc.

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
Lunes 28 de Octubre 2024 (3 semanas hace) • GlobeNewswire Inc.

Form 8-K - Current report
Viernes 18 de Octubre 2024 (1 mes hace) • Edgar (US Regulatory)

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viernes 4 de Octubre 2024 (2 meses hace) • GlobeNewswire Inc.

Más de NewAmsterdam Pharma Company NV Artículos de Noticias

Energy Select Sector SPDR

Invesco QQQ Trust Series 1

American Express

Financial Select Sector

JP Morgan Chase

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones